Overview
On 26 August 2005, orphan designation (EU/3/05/310) was granted by the European Commission to United Therapeutics Europe Ltd., United Kingdom, for treprostinil diethanolamine (oral use) for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Key facts
Active substance |
Treprostinil diethanolamine
|
Intended use |
Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/05/310
|
Date of designation |
26/08/2005
|
Sponsor |
Gran Via Carlos III 94 |
Update history
Date | Update |
---|---|
January 2022 | The sponsorship was transferred to Ferrer Internacional S.A., Spain. |
July 2021 | The sponsor's address was updated. |
February 2019 | The sponsorship was transferred to Unither Therapeutik GmbH, Germany. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: